Home Sectors Consumer Cyclical Stock Under Review: Cavco Industries (NASDAQ: CVCO)

Stock Under Review: Cavco Industries (NASDAQ: CVCO)

15
0
SHARE

Cavco Industries trades as part of the consumer cyclical sector and trades as part of the homebuilding and construction industry. The company CEO is Joseph H. Stegmayer. Cavco Industries Inc designs and produces factory-built homes under the Cavco Homes, Fleetwood Homes, and Palm Harbor Homes brands. It also produces modular homes, park model homes and vacation cabins, as well as commercial structures, among others.

Previous Intraday Trading Performance:

The CVCO stock showed a previous change of 0.14% with an open at 141.23 and a close of 141.35. It reached an intraday high of 144.02 and a low of 137.09.

PR Newswire:  Lifshitz & Miller LLP Announces Investigation of Bluebird Bio, Inc., Cavco Industries, Inc., Edge Therapeutics, Inc., Inuvo, Inc., Lumentum Holdings, Inc., National Commerce Corporation, and Nobilis Health Corp.

Liquidity:

The stock has a market cap of $1.3b with 9.1m shares outstanding, of which the float is 8.5m shares. Trading volume reached 118,350 shares compared to its average volume of 74,284 shares. Based on the current average volume and close price, the trading liquidity is bad, highly speculative and an investor may want to avoid this stock.

Historical Trading Performance:

Over the last five trading days, Cavco Industries shares returned 10.93% and in the past 30 trading days it returned -15.72%. Over three months, it changed -37.13%. In one year it has changed -13.15% and within that year its 52-week high was 261.80 and its 52-week low was 121.40. CVCO stock is 16.43% above its 52 Week Low.

Our calculations show a 200 day moving average of 197.64 and a 50 day moving average of 162.93. Currently CVCO stock is trading -28.48% below its 200 day moving average and may not be a good opportunity to buy as it may continue to trend down.

PR Newswire:  Lifshitz & Miller LLP Announces Investigation of Bluebird Bio, Inc., Cavco Industries, Inc., Edge Therapeutics, Inc., Inuvo, Inc., Lumentum Holdings, Inc., National Commerce Corporation, and Nobilis Health Corp.

Earnings:

The last annual fiscal EPS for the company was reported at 6.68 that ended on 31st of March 2018, which according to the previous close, that is a PE of 21.16. The TTM EPS is 0.00, which comes to a TTM PE of 0.00.

The following are the last four quarter reported earnings per share:
09-30-2018:  1.67
06-30-2018:  2.12
03-31-2018:  2.40
12-31-2017:  0.00

Base on our calculations, the intrinsic value per share is 101.59, which means it may be overvalued by -39.14%

Indicators to Watch:

Based on the latest filings, there is 6.40% of insider ownership and 151.60% of institutional ownership. Short-interest is 0, which is 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio is 0.00.

The current calculated beta is 1.88

SeekingAlpha:  9.2% Dividend Yield With Earnings Growth From Granite Point Merits A Closer Look

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 17.37%, return on assets is 11.56%, profit margin is 7.44%, price-to-sales is 1.66 and price-to-book is 2.46.

Company Scores:

All scores are out of six:
 1  :Valuation Score
 5  :Past Performance Score
 6  :Financial Strength Score
 2  :Future Growth Score
 0  :Dividend Score
 3  :Overall Score

SHARE
John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.

LEAVE A REPLY

Please enter your comment!
Please enter your name here